Literature DB >> 24326684

An MDS xenograft model utilizing a patient-derived cell line.

G W Rhyasen1, M Wunderlich2, K Tohyama3, G Garcia-Manero4, J C Mulloy2, D T Starczynowski1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24326684      PMCID： PMC4215634          DOI： 10.1038/leu.2013.372

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells.

Authors:  Daniella M Bahia Kerbauy; Vladimir Lesnikov; Beverly Torok-Storb; Eileen Bryant; H Joachim Deeg
Journal:  Blood       Date:  2004-10-01       Impact factor: 22.113

2.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Authors:  Pierre Fenaux; Aristoteles Giagounidis; Dominik Selleslag; Odile Beyne-Rauzy; Ghulam Mufti; Moshe Mittelman; Petra Muus; Peter Te Boekhorst; Guillermo Sanz; Consuelo Del Cañizo; Agnes Guerci-Bresler; Lars Nilsson; Uwe Platzbecker; Michael Lübbert; Bruno Quesnel; Mario Cazzola; Arnold Ganser; David Bowen; Brigitte Schlegelberger; Carlo Aul; Robert Knight; John Francis; Tommy Fu; Eva Hellström-Lindberg
Journal:  Blood       Date:  2011-07-13       Impact factor: 22.113

Review 4.  Human factor-dependent leukemia cell lines.

Authors:  K Tohyama
Journal:  Int J Hematol       Date:  1997-06       Impact factor: 2.490

5.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.

Authors:  M Wunderlich; F-S Chou; K A Link; B Mizukawa; R L Perry; M Carroll; J C Mulloy
Journal:  Leukemia       Date:  2010-08-05       Impact factor: 11.528

6.  Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.

Authors:  A Matsuoka; A Tochigi; M Kishimoto; T Nakahara; T Kondo; T Tsujioka; T Tasaka; Y Tohyama; K Tohyama
Journal:  Leukemia       Date:  2010-02-04       Impact factor: 11.528

7.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

Authors:  Wendy W Pang; John V Pluvinage; Elizabeth A Price; Kunju Sridhar; Daniel A Arber; Peter L Greenberg; Stanley L Schrier; Christopher Y Park; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-06       Impact factor: 11.205

8.  AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.

Authors:  Mark Wunderlich; Benjamin Mizukawa; Fu-Sheng Chou; Christina Sexton; Mahesh Shrestha; Yogen Saunthararajah; James C Mulloy
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

9.  Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome.

Authors:  K Tohyama; H Tsutani; T Ueda; T Nakamura; Y Yoshida
Journal:  Br J Haematol       Date:  1994-06       Impact factor: 6.998

10.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Authors:  Garrett W Rhyasen; Lyndsey Bolanos; Jing Fang; Andres Jerez; Mark Wunderlich; Carmela Rigolino; Lesley Mathews; Marc Ferrer; Noel Southall; Rajarshi Guha; Jonathan Keller; Craig Thomas; Levi J Beverly; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; Jaroslaw P Maciejewski; James C Mulloy; Daniel T Starczynowski
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743
View more
  22 in total

Review 1.  Energy metabolism and drug response in myeloid leukaemic stem cells.

Authors:  Alfonso E Bencomo-Alvarez; Andres J Rubio; Mayra A Gonzalez; Anna M Eiring
Journal:  Br J Haematol       Date:  2019-06-24       Impact factor: 6.998

Review 2.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

3.  Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome.

Authors:  Angel Y F Kam; Sadhna O Piryani; Chad M McCall; Hee Su Park; David A Rizzieri; Phuong L Doan
Journal:  Clin Cancer Res       Date:  2019-04-05       Impact factor: 12.531

4.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Authors:  Jie Sun; Xin He; Yinghui Zhu; Zonghui Ding; Haojie Dong; Yimei Feng; Juan Du; Hanying Wang; Xiwei Wu; Lei Zhang; Xiaochun Yu; Allen Lin; Tinisha McDonald; Dandan Zhao; Herman Wu; Wei-Kai Hua; Bin Zhang; Lifeng Feng; Kaoru Tohyama; Ravi Bhatia; Philipp Oberdoerffer; Yang Jo Chung; Peter D Aplan; Jacqueline Boultwood; Andrea Pellagatti; Samer Khaled; Marcin Kortylewski; Flavia Pichiorri; Ya-Huei Kuo; Nadia Carlesso; Guido Marcucci; Hongchuan Jin; Ling Li
Journal:  Cell Stem Cell       Date:  2018-08-23       Impact factor: 24.633

5.  Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.

Authors:  P Sontakke; M Carretta; J Jaques; A Z Brouwers-Vos; L Lubbers-Aalders; H Yuan; J D de Bruijn; A C M Martens; E Vellenga; R W J Groen; J J Schuringa
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

6.  A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.

Authors:  Jing Fang; Xiaona Liu; Lyndsey Bolanos; Brenden Barker; Carmela Rigolino; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; H Leighton Grimes; Celia Fontanillo; Kakajan Komurov; Kyle MacBeth; Daniel T Starczynowski
Journal:  Nat Med       Date:  2016-06-13       Impact factor: 53.440

7.  Simultaneous quantitation of oxidized and reduced glutathione via LC-MS/MS: An insight into the redox state of hematopoietic stem cells.

Authors:  Dustin Carroll; Diana Howard; Haining Zhu; Christian M Paumi; Mary Vore; Subbarao Bondada; Ying Liang; Chi Wang; Daret K St Clair
Journal:  Free Radic Biol Med       Date:  2016-05-19       Impact factor: 7.376

8.  β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).

Authors:  Liping Li; Yue Sheng; Wenshu Li; Chao Hu; Nupur Mittal; Kaoru Tohyama; Amber Seba; You-Yang Zhao; Howard Ozer; Tongyu Zhu; Zhijian Qian
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

9.  Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs.

Authors:  Tomoya Muto; Callum S Walker; Kwangmin Choi; Kathleen Hueneman; Molly A Smith; Zartash Gul; Guillermo Garcia-Manero; Averil Ma; Yi Zheng; Daniel T Starczynowski
Journal:  Nat Immunol       Date:  2020-04-20       Impact factor: 25.606

10.  Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.

Authors:  Angel Y F Kam; Sadhna O Piryani; Chang-Lung Lee; David A Rizzieri; Neil L Spector; Stefanie Sarantopoulos; Phuong L Doan
Journal:  Mol Cancer Res       Date:  2021-01-29       Impact factor: 6.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.